I believe the generic strategy is a very good one. I came to the realisation early on that topical drugs NDA or ANDA for the US market are very very hard to get approval for. The flip side is once approved the drugs earn money for decades. Its the implementation that’s proving suspect. It’s been fortuitous that any missteps ( I don’t know of any ) that ACR may have done, can be sheeted to Covid and the the FDA being swamped by responding to Covid. As for Harris Pharma what the hell happen there?
Add to My Watchlist
What is My Watchlist?
